Etomidate

Etomidate
	Above: molecular structure of (R)-etomidate Below: 3D representation of an etomidate molecule
Clinical data
Trade names	Amidate, Hypnomidate, Tomvi
AHFS/Drugs.com	Monograph
License data	US DailyMed: Etomidate;
Routes of; administration	Intravenous
ATC code	N01AX07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	76%
Metabolism	Ester hydrolysis in plasma and liver
Elimination half-life	75 minutes
Excretion	Urine (85%) and Bile duct (15%)
Identifiers
	IUPAC name Ethyl 3-[(1R)-1-phenylethyl]imidazole-5-carboxylate;
CAS Number	33125-97-2 ;
PubChem CID	36339;
DrugBank	DB00292 ;
ChemSpider	33418 ;
UNII	Z22628B598;
KEGG	D00548 ;
ChEMBL	ChEMBL23731 ;
CompTox Dashboard (EPA)	DTXSID5023033 ;
ECHA InfoCard	100.046.700
Chemical and physical data
Formula	C14H16N2O2
Molar mass	244.294 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	67 °C (153 °F)
Boiling point	392 °C (738 °F)
	SMILES O=C(OCC)c1cncn1C(c2ccccc2)C;
	InChI InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3 ; Key:NPUKDXXFDDZOKR-UHFFFAOYSA-N ;
	(verify)

Etomidate (USAN, INN, BAN; marketed as Amidate) is a short-acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation for short procedures such as reduction of dislocated joints, tracheal intubation, cardioversion and electroconvulsive therapy. It was developed at Janssen Pharmaceutica in 1964 and was introduced as an intravenous agent in 1972 in Europe and in 1983 in the United States.

The most common side effects include venous pain on injection and skeletal muscle movements.